[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000517:prevention & control*; D010347:Patient Care Planning; D010974:Platelet Aggregation / Q000187:drug effects; D012008:Recurrence; D012306:Risk; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D013988:Ticlopidine
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D000960:Hypolipidemic Agents; D013876:Thiophenes; D004176:Dipyridamole; D013988:Ticlopidine; D001241:Aspirin; D013442:Sulfinpyrazone
Nabehandeling van hartinfarctpatiénten om de kans op een volgend infarct te verminderen.